CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	[1]
Revenue:
Total revenue	$ 55,232	$ 98,427
Operating costs and expenses:
Cost of goods sold	0	30,686
Research and development (including $2,636 and $277 for the year ended December 31, 2025 and 2024, respectively, from a related party)	117,330	120,908
General and administrative	68,673	76,751
Restructuring and impairment	9,331	15,670
Gain on sale of the Huntsville manufacturing facility	0	(40,390)
Total operating costs and expenses	195,334	203,625
Loss from operations	(140,102)	(105,198)
Non-operating income (expense):
Non-cash interest expense on liabilities related to the sales of future royalties	(26,184)	(28,112)
Interest income	10,438	14,500
Other income (expense), net (including $1,110 and $0 for the year ended December 31, 2025 and 2024, respectively, from a related party)	361	(390)
Total non-operating income (expense), net	(15,385)	(14,002)
Loss before benefit for income taxes and equity method investment	(155,487)	(119,200)
Benefit for income taxes	(138)	(239)
Loss before equity method investment	(155,349)	(118,961)
Loss from equity method investment	(8,727)	0
Net loss	$ (164,076)	$ (118,961)
Basic net loss per share (in dollars per share)	$ (9.73)	$ (8.68)
Diluted net loss per share (in dollars per share)	$ (9.73)	$ (8.68)
Weighted average shares outstanding used in computing basic net loss per share (in shares)	16,870,930	13,710,775
Weighted average shares outstanding used in computing diluted net loss per share (in shares)	16,870,930	13,710,775
Product sales
Revenue:
Total revenue	$ 0	$ 33,563
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	54,932	64,267
License, collaboration and other revenue
Revenue:
Total revenue	$ 300	$ 597

[1] All share and per share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 8).